A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
Authors
Keywords
-
Journal
Current Opinion in HIV and AIDS
Volume 17, Issue 1, Pages 22-31
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-11-20
DOI
10.1097/coh.0000000000000708
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine
- (2021) Amy G. Cutrell et al. AIDS
- Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
- (2021) Daryl Hodge et al. CLINICAL PHARMACOKINETICS
- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Long-acting cabotegravir + rilpivirine for HIV-1 treatment
- (2021) Susan Swindells et al. AIDS
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
- (2021) Raphael J. Landovitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
- (2021) Graham H R Smith et al. Open Forum Infectious Diseases
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2021) Hans Jaeger et al. Lancet HIV
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Cabotegravir long-acting protects macaques against repeated penile SHIV exposures
- (2020) Charles Dobard et al. JOURNAL OF INFECTIOUS DISEASES
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2020) Kenneth H Mayer et al. LANCET
- “A dream come true”: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania
- (2020) Deanna Kerrigan et al. PLoS One
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy
- (2020) Giuliano Rizzardini et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Long-acting injectable therapy
- (2019) Ronald D’Amico et al. Current Opinion in HIV and AIDS
- Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
- (2018) Deanna Kerrigan et al. PLoS One
- Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
- (2018) Raphael J. Landovitz et al. PLOS MEDICINE
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- Planning for HIV preexposure prophylaxis introduction
- (2016) Sinéad Delany-Moretlwe et al. Current Opinion in HIV and AIDS
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
- (2015) David A Margolis et al. LANCET INFECTIOUS DISEASES
- Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
- (2014) C. D. Andrews et al. SCIENCE
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
- (2012) Jared M. Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
- (2010) Robert M. Grant et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search